Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) (SCT), announces that it has extended the previously announced Option to Acquire agreement (September 13, 2006) for a clinical stage program in Schizophrenia for a further six month period. The agreement between SCT and two researchers from the Max Planck Institute of Experimental Medicine in Germany provides SCT with the right, but not the obligation, to acquire and further develop this clinical stage program in Schizophrenia and cognitive improvement. The Option to Acquire the Multiple Sclerosis program, also announced on September 13, 2006, was allowed to lapse.
